Personalized, Allogeneic Cell Therapy of Cancer
Generated by a Claude Opus 4.7 agent (max thinking effort, 1M-context). Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
cancer (personalized allogeneic T cell therapy targeting tumor neoantigens)
Modality
CAR T
Mechanism
allogeneic neoantigen-reactive T cell therapy
Target
tumor neoantigens
rNPV Envelope
Low
-$76.4M
costs +25% · peak −25%
Base
-$16.1M
cumulative PoS 10.0%
High
$44.2M
costs −25% · peak +25%
Allogeneic CAR-T has high manufacturing and safety-monitoring costs, so early-stage costs sit at the upper end of cell/gene anchors. The CAR-T modality improves Phase 1/2 transition assumptions, but neoantigen personalization and allogeneic rejection risk keep late-stage PoS conservative.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.80
Modality fit · 30%
1.00
Whitespace · 30%
0.50
Composite 0.770 — composite-score rank #1 of 10 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#5) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
TECELRA / afami-cel (Adaptimmune) — autologous MAGE-A4 TCR-T
First-ever FDA-approved engineered cell therapy for a solid tumor; closest commercial precedent for cellular immunotherapy targeting tumor antigens in solid disease.
Criteria 1 and 2: same regulatory + commercial precedent class (engineered T-cell therapy, solid tumor, MHC-restricted antigen recognition). Different cell-engineering approach (engineered TCR vs natural TCR repertoire) but same archetype: tumor-antigen-directed adoptive cellular therapy.
Amtagvi / lifileucel (Iovance) — autologous tumor-infiltrating lymphocyte (TIL)
First-ever approved cell therapy for a solid tumor (Feb 2024). Closest mechanistic analog for natural-TCR-repertoire-based tumor-reactive T-cell therapy — Amtagvi is autologous TIL from the patient's own tumor; this asset's framework is donor-derived neoantigen-reactive T cells.
Criteria 1 and 4: same therapeutic class (adoptive cell therapy with natural TCR repertoire targeting tumor antigens, not engineered CAR or TCR). Iovance FY2025 actual ~$264M product revenue; $1.0B peak reflects long-run melanoma + label expansions.
ALLO-501A / cema-cel (Allogene) — allogeneic anti-CD19 CAR-T
Closest allogeneic CAR-T development benchmark for off-the-shelf manufacturing and dosing.
Criteria 4: same allogeneic CAR-T modality and hematologic oncology development path.
CB-010 (Caribou Biosciences) — genome-edited allogeneic CAR-T
CRISPR-edited allo CAR-T comparator for early clinical safety and durability risk.
Criteria 4: same off-the-shelf edited CAR-T modality with comparable manufacturing risk.
Yescarta (Kite/Gilead) — axicabtagene ciloleucel
Launched CAR-T revenue benchmark before discounting for allogeneic and neoantigen risk.
Criteria 2 and 4: launched CAR-T oncology comparator and commercialization benchmark.
ADI-001 (Adicet Bio) — allogeneic gamma-delta CAR-T
Allogeneic immune-cell comparator for off-the-shelf cell-therapy platform risk.
Criteria 4: same allogeneic cellular-therapy manufacturing and early clinical risk.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $30.0M | 24 mo | 50.0% | [0] [1] [5] |
| Phase I | $90.0M | 18 mo | 78.0% | [0] [1] [6] |
| Phase II | $220.0M | 30 mo | 52.0% | [1] [3] [6] |
| Phase III | $320.0M | 36 mo | 56.0% | [2] [4] [6] |
| NDA/BLA Review | $18.0M | 12 mo | 88.0% | [2] [4] [6] |
Multiplier handling: Eligible multipliers (biomarker_1.7x, car_t_1.73x, fast_track_or_rmat) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$1.00B peak · WACC 14.0%
Peak revenue. $1.0B peak assumes platform breadth across selected solid-tumor indications, anchored to Amtagvi's $1.0B long-run TIL ceiling (Iovance FY2025 actual ~$264M, growing) and discounted from Yescarta's hematologic CAR-T economics. Single-indication standalone economics would be well below this; the $1.0B assumes a partnership / platform structure.
WACC. Cell therapy manufacturing and allogeneic immunology risk warrant a premium WACC despite VC-fundable upside.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$16.1M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$333.4M
P25
-$151.7M
P50 (median)
-$33.5M
P75
-$17.4M
P95
$801.6M
Prob ≥ 0
9.6%
Comparable launch curves
Revenue trajectories of named comparators
TECELRA / afami-cel (Adaptimmune) — autologous MAGE-A4 TCR-T
Launched 2024 · peak $237.5M (estimated)
Evidence register
9 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
regulatory | high | ||
regulatory | high | ||
ALLO-501A active allogeneic CAR-T comparator comparators[0] | ClinicalTrials.gov NCT04416984: ALLO-501A in large B-cell lymphoma trial_disclosure | 2020-06-11 | high |
CB-010 allogeneic edited CAR-T comparator comparators[1] | ClinicalTrials.gov NCT04637763: CB-010 ANTLER trial trial_disclosure | 2020-11-20 | high |
Yescarta approval and CAR-T revenue benchmark comparators[2] | FDA Yescarta cellular and gene therapy product page regulatory | 2017-10-18 | high |
ADI-001 allogeneic gamma-delta comparator comparators[3] | ClinicalTrials.gov NCT04735471: ADI-001 CAR gamma-delta T cells trial_disclosure | 2021-02-02 | high |
Yescarta commercial scale peak_revenue_usd | Gilead Sciences full-year 2024 financial results company_filing | 2025-02-11 | high |
Cell/gene stage-cost bound stage_profile.phase_2.cost_usd_m | Wouters et al., Estimated R&D Investment Needed to Bring a New Medicine to Market, JAMA 2020 peer_review | 2020-03-03 | medium |
CAR-T PoS adjustment stage_profile.phase_1.pos | BIO/QLS/Informa Clinical Development Success Rates 2011-2020 peer_review | 2021-02-17 | medium |
Thesis
Why this asset earns its top-10 rank
**Important framing.** The JHU listing for this invention describes obtaining lymphocytes from a partially or fully HLA-matched healthy donor and activating/expanding T cells reactive to tumor neoantigens — i.e., enriched donor T-cells using their natural TCR repertoire, not an engineered CAR or TCR. The case-study cohort assigns this asset to the coarse "car_t" modality bucket (the closest available class), but the closest commercial precedents are Amtagvi (autologous TIL, approved Feb 2024) and TECELRA (autologous engineered TCR-T, approved Aug 2024), both approved for solid tumors via natural- or engineered-receptor recognition of tumor antigens — neither is a CD19/CD20 CAR-T. The full-cohort rNPV pass will add a discrete adoptive-cell-therapy modality class with its own per-stage LoA baseline; until then, treat the modality_pos = 1.00 subscore as inherited from the bucket assignment, not as a CAR-T-class precedent. Documented in docs/jhtv-known-limitations.md.
The asset combines two hard ideas: off-the-shelf donor-derived cellular therapy and personalized tumor neoantigen recognition. The reconciliation implied by the JHU listing is donor-bank style — pre-screen partially-HLA-matched donors for T-cell repertoires that recognize public/shared neoantigens (e.g., KRAS G12D, p53 R175H), then enrich and expand. The listing does not specify per-patient bespoke selection vs pre-banked TCR libraries, which is a real diligence gap that a CMO advisor will probe.
Comparator framing. TECELRA (afami-cel) and Amtagvi (lifileucel) are the closest solid-tumor commercial precedents (both approved 2024, both adoptive cell therapy with MHC-restricted antigen recognition, both first-of-kind regulatory paths). ALLO-501A, CB-010, Yescarta, and ADI-001 are CD19/CD20 CAR-T comparators included as adjacent allogeneic / autologous cell-therapy economics anchors — they share the cell-therapy CMC + manufacturing risk profile but target surface antigens MHC-independently rather than tumor neoantigens via TCR-MHC. The engine result is -$76.4M to $44.2M, with a base rNPV of -$16.1M and cumulative PoS of 10.0%; the negative base rNPV with positive high case is consistent with a partnership-candidate framing — a single standalone-equity bet on this asset is hard to underwrite, but the platform value compounds inside an existing cell-therapy developer's manufacturing + clinical infrastructure.
The verdict is partnership-shaped, not standalone VC. It earns a top-10 slot because the clinical upside is real (solid-tumor cellular immunotherapy is a multi-billion-dollar unmet need) and the comparator category is now precedented (Amtagvi, TECELRA), but the investment case should be staged around (a) disclosure of the donor-bank vs per-patient manufacturing workflow, (b) early persistence and HLA-matching data, and (c) selection of a lead solid-tumor indication with a defined neoantigen target.
Key risks
Asset-specific, not generic biotech risks
- JHU listing does not disclose whether the donor T-cell selection is pre-banked (public neoantigens) or per-patient bespoke; this distinction drives manufacturing economics and the investability of the platform.
- Partially HLA-matched donor cells may not persist long enough for durable tumor control; allogeneic CAR-T persistence has been the limiting factor across ALLO-501A and CB-010 programs.
- Modality bucket assignment ('car_t') in the case-study cohort is a coarse approximation; the asset is mechanistically closer to Amtagvi (TIL) or TECELRA (TCR-T) — full-cohort rNPV will recategorize. See docs/jhtv-known-limitations.md.
- Lead solid-tumor indication is not specified in the JHU listing; PoS calibration and peak revenue assumptions therefore carry indication-selection risk that a CMO will price into the early term sheet.
- Autologous (Amtagvi) and engineered-receptor (TECELRA) competitors have first-mover regulatory advantage; the donor-derived allogeneic value proposition must clearly out-perform on cost-of-goods or manufacturing scalability to compete.